Navigation Links
PAR in Medical Technology

Spherix Reports First Quarter 2009 Earnings

...ockholders' equity Preferred stock, $0.01 par value, 2,000,000 shares authorized; ... - - Common stock, $0.005 par value, 50,000,000 shares authorized; ... 72,188 Paid-in capital in excess of par value 27,610,426 27,602,486 Treasury s...

Bionovo Announces First Quarter 2009 Highlights and Financial Results

...d contingencies Shareholders' equity: Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outs...ding - - Common stock $0.0001 par value, 190,000,000 shares authorized, 76,363,101 and 76,3...

Strativa Pharmaceuticals Provides Product Pipeline Update

... products division of a wholly owned subsidiary of par Pharmaceutical Companies, Inc. (NYSE: PRX ), tod...aceuticals is the proprietary products division of par Pharmaceutical, Inc. Strativa is committed to deve...ease visit www.strativapharma.com . About par Pharmaceutical ...

Elbow Ligament Reconstruction Appears Not to Affect Future Professional Advancement in Baseball

...it is heartening to see that the procedure can be successful in allowing future professional athletes to the reach the highest level of competition on par with their peers," said Carolan. The American Orthopaedic Society for Sports Medicine (AOSSM) is a world leader in sports medicine education, res...

Pharmasset Reports Fiscal Year End 2008 Financial Results

...bilities 33,794,724 16,908,073 COMMITMENTS & CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,340,498 and 21,232,991 shares issued and outstanding at September 30,...

Alfacell Provides ONCONASE(R) NDA Submission Update

...iple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd....

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

...ckholders' Equity Preferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $.001 par value, 41,130,270 and 40,991,385 issued and outstanding as of Septe...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

...FS is an effective prophylactic FVIII replacement product has 'jump started' the standard of hemophilia care in the United States so that it is now on par with other developed countries, especially those in Western and Northern Europe." The FDA approval of Kogenate(R) FS for routine prophylaxis in chil...

Pharmasset Reports Financial Results for Quarter Ended June 30, 2008

...45 16,908,073 -------------------------- COMMITMENTS STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,751,503 and 21,232,991 shares issued and outstanding at June 30, 2008 (unaudited) and September 30, 200...

MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development

...uding the recently announced licensing of our thin film formulation of ondansetron, an anti-emetic therapy, to Strativa Pharmaceuticals, a division of par Pharmaceuticals. Our expectation is to partner our PharmFilm(R) escitalopram oxalate product with a pharmaceutical company that is competitively posit...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

...ia multiple molecular mechanisms of action. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...ase visit http://www.strativapharma.com . About par Pharmaceutical par Pharmaceutical, Inc. develops, manufactures and ma...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

...completed by the end of calendar year 2008. Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong...

Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis

...rmaceuticals, the proprietary products division of par Pharmaceutical Companies, Inc. (NYSE: PRX ) today...gredient at the site of infection. In July 2007, par Pharmaceutical, Inc. entered into an exclusive licensing agreement under which par received commercialization rights in the U.S. to B...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

...elopment for this target market. Therefore, the Company will direct its resources to concentrate on other drug programs. Immtech's licensing partners, par Pharmaceutical Companies, Inc. and BioAlliance Pharma SA, remain in full support of the Company. Immtech was informed in late December 2007 that a s...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

... 16,908,073 ------------------------------ COMMITMENTS STOCKHOLDER'S EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 21,288,614 and 21,232,991 shares issued and outstanding at December 31, 2007 and September 30, 2007, r...

Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference

... second-generation polymerase inhibitor, IDX184, delivered multi-log viral load reductions in HCV genotype-1 infected chimpanzees in just 4 days -- on par with the antiviral activity reported to date from protease inhibitors currently in development." Sommadossi continued, "In 2008, we look forward to ...

Immtech Reports Fiscal Second Quarter 2008 Results

...can sleeping sickness trial. During the three-month period ended September 30, 2007, several significant milestones were achieved. In addition to the par Pharmaceutical agreement, Immtech received orphan drug status from the USFDA for pafuramidine to treat malaria and African sleeping sickness, added a ...

Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

...itments and contingencies Stockholders' equity: Preferred stock, $0.001 par value 5,000,000 shares authorized at September 30, 2007 and Decembe... 31, 2006 - - Common stock, $0.001 par value: Authorized shares, 75,000,000 at September 30, 2007 and D...

Chinese SFDA Grants Immtech Fast Track Status

...entered into an exclusive licensing agreement with par Pharmaceutical Companies, Inc. (NYSE: PRX ) under which par will receive commercialization rights in the U.S. ...lease visit http://www.immtechpharma.com . About par Pharmaceutical Companies, Inc. ...

Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

...estors purchased 23,605,551 Units ("Units") at a price of $1.08 per Unit with each Unit consisting of four shares of the Company's common stock, $0.01 par value, and a warrant to purchase one share of common stock. 13,842,590 of the Units were purchased for cash, with the balance of 9,962,961 Units issue...

Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results

...e preferred stock - - Common stock 6,190 6,149 Capital in excess of par 329,237 327,228 Treasury stock (5,321) (5,321) Accumulated deficit ...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

...tablets. As previously announced, in November 2006 par entered into a supply and distribution agreement w...traZeneca's TOPROL-XL(R) extended release tablets. par began shipping 25 mg tablets of generic Toprol-XL ...king metoprolol succinate extended release. About par ...

DVT Awareness Survey Findings: Heart and Respiratory Patients

...s know only as much about it as the general population. * 52% of heart/respiratory patients have some knowledge about DVT -- on par with the general population (51%). * 40% of heart/respiratory patients have heard or read about DVT recently, the same percentage as...
Other Tags
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/22/2014)... Physicians in China are most eagerly awaiting ... non-Hodgkin’s lymphoma (NHL), according to a new report from ... firm. MabThera is the only biologic available to treat ... of NHL. , According to Kantar Health’s report, “Biosimilars ... NHL in China has been growing and is expected ...
(Date:12/22/2014)... Only weeks following the announcement that ... to have a battery manufacturer create 29 well-paying jobs ... ) is launching in Henderson to deliver yet ... strong manufacturing sector is going to build a stronger ... “and TalkLocal works with small businesses that rely on ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
Other Contents